Patents by Inventor Catherine Pillet

Catherine Pillet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease
    Patent number: 11306063
    Abstract: The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: April 19, 2022
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Universite d'Aix Marseille
    Inventors: Marie-Odile Fauvarque, Magda Mortier, Catherine Pillet, Carmen Aguilar, Emmanuelle Soleilhac, Caroline Barette, Vincent Remusat, Thierry Terme, Patrice Vanelle
  • Synthetic lethal drug combination for treating renal cell carcinoma
    Patent number: 10322133
    Abstract: The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 18, 2019
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut National de la Sante et de la Recherche Medicale
    Inventors: Sofia Giacosa, Catherine Pillet, Claude Cochet, Odile Filhol, Caroline Barette, Emmanuelle Soleilhac
  • Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease
    Publication number: 20190169136
    Abstract: The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicants: Commissariat a l'Energie Atomique et aux Energies Alternatives, Universite Grenoble Alpes, Universite d'Aix Marseille
    Inventors: Marie-Odile Fauvarque, Magda Mortier, Catherine Pillet, Carmen Aguilar, Emmanuelle Soleilhac, Caroline Barette, Vincent Remusat, Thierry Terme, Patrice Vanelle
  • A Synthetic Lethal Drug Combination for Treating Renal Cell Carcinoma
    Publication number: 20180256587
    Abstract: The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 13, 2018
    Applicants: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sofia Giacosa, Catherine Pillet, Claude Cochet, Odile Filhol, Caroline Barette, Emmanuelle Soleilhac